IAVI Report

Quarraisha and Salim Abdool Karim received the Lasker Prize for public service in recognition of their decades-spanning work on HIV prevention, treatment, and advocacy.

Discovery medicine trials are underway to evaluate several HIV vaccine immunogens designed to prime the immune system to make broadly neutralizing antibodies. What comes next?

Manufacturing proteins is notoriously expensive and complex. Will new ways of producing them come from continuous processes, Sunflowers, or even…goat milk?

Last week at AIDS 2024 many experts warned that the global response is at a critical inflection point. Will efforts to develop and provide access to new prevention options drive much-needed progress?

Assessing two decades of a European-African research partnership with an anxious eye on the future.

Voss and his team are using gene editing technologies to reprogram B cells to make broadly neutralizing antibodies against HIV. Will this be a route to a functional cure?

Recent data suggest these engineered proteins can prevent the parasitic infection, but cost will ultimately determine if they are made available in low- and middle-income countries where they are needed most.

The COVID-19 experience, along with lingering manufacturing and delivery concerns, is prompting a harder look at the future of antibody-based treatment and prevention for infectious diseases.

Researchers at CROI discuss progress on the long road to developing an HIV vaccine.

Infections are at the highest levels since 1950 and fear of antimicrobial resistance is fueling new concerns over this old pathogen.

Nearly 150 years after the discovery of tuberculosis, researchers are still unraveling the fundamental biology and epidemiology of the germ and how best to defeat it.

The scientific implications of artificial intelligence loom large. One tangible application is designing better vaccines.